ORIGINAL RESEARCH ORİJİNAL ARAŞTIRMA

DOI: 10.31609/jpmrs.2024-105182

New Inflammatory Indexes in Diabetic Neuropathy

Diyabetik Nöropatide Yeni İnflamatuar İndeksler

Türkan TUNCER[a], Emel SABAZ KARAKEÇİ[a]

[a]Sağlık Bilimleri University Elazığ Fethi Sekin City Hospital, Clinic of Physical Medicine and Rehabilitation, Elazığ, Türkiye

ABSTRACT Objective: The aim of this study was to investigate systemic inflammatory indices in diabetic neuropathy (DN), which is one of the microvascular, common and preventable complications of diabetes that causes morbidity and mortality in Type 2 Diabetes Mellitus (DM) patients. **Material and Methods:** 414 patients with DM were divided into 2 groups according to the presence of DN. Platelet, lymphocyte, monocyte counts, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratios (MLR), systemic inflammatory index (SII), systemic inflammatory response index (SIRI), Hemoglobin A1c (HbA1c) levels were analysed in each group. **Results:** No difference was found in both groups in terms of age and gender. 207 patients with DN and 207 patients with DM without DN symptoms and findings were included in the study. When the 2 groups were compared, a statistically significant increase in lSII, SIRI, HbA1c level and NLR rate was detected in the DN group ($p<0.001$). A positive correlation was found between SII and SIRI and HbA1c level. Sensitivity and specificity were 71.69% and 83.33%, respectively, for SII in detecting the presence of DN. For SIRI, sensitivity was 69.04% and specificity was 62.22%. **Conclusion:** In the DN positive group, this elevation in systemic inflammation parameters, which are inexpensive and can be easily calculated in routine blood tests, may be helpful in predicting the presence of chronic microvascular disease such as neuropathy.

Keywords: Inflammation; diabetic neuropathy; systemic immune-inflammation index; systemic inflammatory response index

ÖZET Amaç: Bu çalışmanın amacı, Tip 2 diyabet (DM) hastalarında morbidite ve mortaliteye neden olan, diyabetin mikrovasküler, yaygın ve önlenebilir komplikasyonlarından biri olan diyabetik nöropatide (DN) sistemik inflamatuar indekslerin araştırılmasıdır. **Gereç ve Yöntemler:** Tip 2 DM'li 414 hasta DN varlığına göre 2 gruba ayrıldı. Her 2 grupta hastaların serum trombosit, lenfosit, monosit sayıları, nötrofil/lenfosit oranı [neutrophil/lymphocyte ratio (NLR)], trombosit/lenfosit oranı [platelet/lymphocyte ratio (PLR)], monosit/lenfosit oranları [monocyte/lymphocyte ratios (MLR)], sistemik inflamatuar indeks [systemic inflammatory index (SII)], sistemik inflamatuar yanıt indeksi [systemic inflammatory response index (SIRI)], Hemoglobin A1c (HbA1c) seviyeleri değerlendirildi. **Bulgular:** Her 2 grupta yaş ve cinsiyet açısından farklılık saptanmadı. Çalışmaya DN semptom ve bulguları olan 207 DM'li hasta ile nöropati semptom ve bulguları olmayan 207 DM'li hasta dâhil edildi. Her 2 grup karşılaştırdığında DN grubunda SII, SIRI, HbA1c düzeyi ve NLR oranında istatistiksel anlamlı yükseklik saptandı ($p<0,001$). SII ile SIRI ve HbA1c düzeyi arasında pozitif korelasyon bulundu. DN varlığını tespit etmede SII'nin duyarlılığı ve özgüllüğü sırasıyla %71,69 ve %83,33 idi. SIRI için duyarlılık %69,04 ve özgüllük %62,22 idi. **Sonuç:** DN pozitif grupta ucuz olan ve rutin kan testlerinde kolaylıkla hesaplanabilen sistemik inflamasyon parametrelerindeki yükselme, nöropati gibi kronik mikrovasküler hastalık varlığının öngörülmesinde yardımcı olabilir.

Anahtar Kelimeler: İnflamasyon; diyabetik nöropati; sistemik immün inflamasyon indeksi; sistemik inflamasyon yanıt indeksi

Diabetic neuropathy (DN) is a microvascular, widespread complication of diabetes that causes morbidity and mortality in Type 2 Diabetes Mellitus (DM) patients and can be prevented with early diagnosis and treatment. Considering its complications, it is estimated that globally Type 2 DM will be the 7th leading cause of death by 2030.[1,2]

The exact diagnostic criteria and pathophysiological mechanisms of DN are still unclear. It is thought that disruptions in glucose and lipid

Correspondence: Türkan TUNCER
Sağlık Bilimleri University Elazığ Fethi Sekin City Hospital, Clinic of Physical Medicine and Rehabilitation, Elazığ, Türkiye
E-mail: trkntncr23@gmail.com

Peer review under responsibility of Journal of Physical Medicine and Rehabilitation Science.

Received: 18 Aug 2024 ***Received in revised form:*** 22 Jan 2025 ***Accepted:*** 28 Jan 2025 ***Available online:*** 17 Feb 2025

metabolism at the cellular and systemic level lead to activation of various biochemical abnormal pathways and ultimately to the development of chronic inflammation.[3] So far, the most common investigation in the pathophysiology of DN has been on oxidative-nitrosative stress and inflammation. Low-grade inflammation and increased pro and anti-inflammatory cytokine concentrations and other biomarkers that mobilise the immune system have been described in DN. Chronic low-grade inflammation increases the risk of Type 2 DM, atherosclerosis, neurodegeneration and tumour growth and is associated with decreased functional capacity and life span.[4] The fact that this inflammatory activation results in insulin resistance and metabolic disease can be explained by various reasons. Inflammatory signalling pathways may cause inhibition of insulin signalling by directly inhibiting serine phosphorylation in the insulin receptor substrate protein.[5] Another factor is that leukocytes released into circulation by inflammatory mediators strengthen inflammation signalling and tissue remodelling capacity of cells in tissues exposed to cellular stress.[6] Thirdly, secreted inflammatory mediators provide systematic communication with insulin resistance.[6,7]

Important prospective clinical studies have shown a strong association between circulating inflammatory markers and proinflammatory cytokines and the risk of developing Type 2 DM.[8] Recently, complete blood count parameters such as neutrophil/lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are thought to play an important role in inflammatory diseases.[9-12]

Systemic immune-inflammation index (SII), which is calculated by using platelet, neutrophil and lymphocyte counts together, and systemic inflammatory response index (SIRI) are recently defined parameters. In studies, it has been found to be a much more effective marker compared with PLR and NLR in predicting poor prognosis in oesophageal and colon cancer and severe disease in cardiac ischaemia.[13-17] SII uses three blood cell subtypes (neutrophils, lymphocytes and platelets) and reflects the balance between inflammation and immunity responding to inflammation.[18,19] Although there are many studies with the SII, which has been shown to be important in malignancy, cardiac and systemic inflammatory rheumatic diseases and pulmonary diseases, there are limited number of studies in DN. In our study, we aimed to evaluate the SII-SIRI index in DN.

MATERIAL AND METHODS

In this study, 414 patients diagnosed with Type 2 DM in the Physical therapy and rehabilitation clinic of xxx Hospital were analysed. The study was conducted after obtaining approval from the non-interventional research ethics committee of Fırat University local ethic commitee (date: May 25, 2023; no: 2023/09-40). All procedures performed involving human participants were conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants included in the study. The number of patients was based on whether the SII parameter would have an effect on predicting the diagnosis of DN, and the number of people who should be included in the study was obtained by power analysis as 414, with 207 people in each group according to the 2-way hypothesis at 95% confidence level (1-α).

Patients were analysed in two groups as patients with DN and diabetic patients without DN. The diagnosis of DN was confirmed by electromyography and DN symptoms and signs were present in all patients with DN. Platelet, lymphocyte, monocyte counts, NLR, PLR, MLR and Hemoglobin (HbA1c) levels were analysed. SII value was evaluated by (platelet*neutrophil)/lymphocyte count and SIRI value by (neutrophil*monocyte)/lymphocyte measurement.[20,21] Patients with symptoms and laboratory findings of active infection, concomitant inflammatory rheumatic disease, heart failure, renal and hepatic failure, immunosuppressive drug use, and recent surgery were not included in the study.

STATISTICAL ANALYSIS

Statistical analyses were performed using SPSS version 21 software (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). The conformity of the variables to normal distribution was analysed using visual (histogram and probability graphs) and analytical meth-

ods (Kolmogorov-Smirnov/ Shapiro-Wilk tests). Descriptive analyses were performed using mean and standard deviation (mean±standard deviation) for normally distributed variables and median and (minimum-maximum) values for non-normally distributed variables. Normally distributed numerical variables were compared by Independent Samples t-test and non-normally distributed numerical variables were compared by Mann-Whitney U test. For correlation analyses, Pearson test was used for normally distributed numerical variables and Spearman correlation tests were used for non-normally distributed variables. $p<0.05$ results were considered statistically significant. Receiver Operating Characteristic (ROC) was used to determine the best cut-off value for SII, SIRI, NLR, MLR values in the prediction of diabetic polyneuropathy. $p<0.05$ was considered statistically significant.

RESULTS

Diabetic neuropathy was present in 207 of 414 patients included in the study. 60.1% of the patients were female (n=249) and 39.8% (n=165) were male. The mean age of the participants was 59.6±5.2 years. The mean disease duration was 8.23±4.25 years.

No significant difference was found between the two groups in terms of age and platelet value according to the presence of DN. Statistical difference was found in SII, SIRI, HbA1c level and NLR ($p<0.001$). The parameters compared between both groups are given in Table 1.

When the relationship between SII and SIRI and other parameters was analysed, there was a positive correlation between HbA1c level and both parameters. Correlation analysis results are shown in Table 2.

In the ROC analysis for the presence of DN, the area under the curve (AUC) value of the SII parameter was obtained as 0.686 and was statistically significant ($p<0.001$). Sensitivity and specificity were 71.69% and 83.33%, respectively. The AUC value of SIRI parameter was obtained as 0.662 and was statistically significant ($p<0.001$). Sensitivity and specificity were 69.04% and 62.22%, respectively. The AUC value of the NLR parameter was 0.638 and was statistically significant ($p<0.001$). Sensitivity and specificity were 65.04% and 56.11%, respectively. The AUC value of the PLR parameter was 0.581 and was statistically significant. ($p=0.005$). Sensitivity and specificity were 54.42% and 60.56%, respectively. The AUC value of the MLR parameter was 0.589, which was statistically significant ($p=0.002$). Sensitivity was 42.48% and specificity was 71.11%. The result of ROC analysis is given in Table 3 and Figure 1.

TABLE 1: Comparison between groups according to the presence of diabetic neuropathy.

	Pozitive $\bar{X}$±SD	Negative $\bar{X}$±SD	p value
Age	59.8±5.3	59.5±5.2	0.590
Platelet	254.5±58.4	262.2±66.1	0.260
Neutrophil	4.25±1.1	4.8±1.3	**<0.001**
Lymphocyte	2.2±0.7	2.1±0.7	**0.036**
Monocyte	0.63±0.58	0.66±0.35	**0.045**
SII	478.2±215	681.4±362	**<0.001**
SIRI	1.7±7.7	1.67±1.18	**<0.001**
HbA1c	7.95±1.78	8.8±2	**<0.001**
NLR	2.02±0.86	2.61±1.52	**<0.001**
PLR	127.1±67.7	166.1±373	**0.005**
MLR	0.29±0.15	0.36±0.25	**0.002**

Mann-Whitney U testi, SD: Standard deviation; SII: Systemic inflammatory index; SIRI: Systemic inflammatory response index; HbA1c: Hemoglobin A1c; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratios.

TABLE 2: Correlation analysis results.

	SII		SIRI	
	r value	p value	r value	p value
Age	-0.004	0.938	0.003	0.953
HbA1c	0.453	**<0.001**	0.490	**<0.001**
NLR	0.714	**<0.001**	0.690	**<0.001**
PLR	0.679	**<0.001**	0.391	**<0.001**
MLR	0.402	**<0.001**	0.678	**<0.001**

Spearman rank test. SII: systemic inflammatory index; SIRI: Systemic inflammatory response index; HbA1c: Hemoglobin; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratios.

DISCUSSION

In this study, SII, SIRI and other inflammation indices were found to be significantly higher in patients with DN. A positive correlation was found between

TABLE 3: Receiver Operating Characteristic analysis result.						
	AUC (%95 CI)	p value	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
SII	0.686 (0.635-0.737)	**<0.001**	71.69%	83.33%	77.10%	54.55%
SIRI	0.662 (0.609-0.715)	**<0.001**	69.04%	62.22%	68.37%	58.64%
NLR	0.638 (0.585-0.692)	**<0.001**	65.04%	56.11%	65.04%	56.11%
PLR	0.581 (0.525-0.637)	**0.005**	54.42%	60.56%	63.40%	51.42%
MLR	0.589 (0.534-0.644)	**0.002**	42.48%	71.11%	64.86%	49.61%

AUC: The area under the curve; Confidence Interval; SII: Systemic inflammatory index; SIRI: Systemic inflammatory response index; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratios; PPV: Positive predictive value; NPC: Negative predictive value



FIGURE 1: The ROC curve apelin for fibromyalgia syndrome.
ROC: Receiver operating characteristic.
SII: Systemic inflammatory index; SIRI: Systemic inflammatory response index; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratios.

SII and SIRI values and HbA1c level. Specificity of SII and sensitivity of SIRI parameter were found to be higher than other inflammatory markers (such as NLR, PLR, MLR).

SIIis a novel inflammatory metric that is determined by platelet count, neutrophils, and lymphocytes-all of which are crucial in the etiology of inflammation.[19] In the literature, SII has been studied in a wide variety of cancers as well as in conditions considered to be inflammatory diseases such as diabetes and microvascular complications of diabetes.[22-24] Microvascular damage is the main factor of both systemic and local inflammation with the participation of inflammatory cells such as neutrophils, monocytes, lymphocytes and platelets, which are associated with the development of diabetic nerve damage in patients with diabetes.[25,26] Peripheral blood neutrophils are specifically associated with the etiology of diabetic organ damage because hyperglycemia raises the quantity of neutrophils in circulation. Neutrophils migrate to the site of damage via chemokines. Thus, the inflammatory cascade starts.[27] Leukocytes inflict oxidative and proteolytic damage on cells, as well as inflammatory processes that are not dependent on infection.[28] Numerous cytokines and transcription factors, such as tumor necrosis factor-α, tumor necrosis factor-β, interleukin-1 (IL-1), and transforming growth factor, are secreted by activated leukocytes and play a crucial role in inflammation.[29-32] Because SII is influenced by both neutrophils and lymphocytes, increased SII levels in diabetic neuropathy are seen in our research. The results of this research might have significant therapeutic ramifications for the prompt detection and management of diabetic neuropathy in individuals with Type 2 DM.

Distal symmetric sensorimotor polyneuropathy is the most prevalent kind of neuropathy that affects both small and big fibers. It is often asymptomatic.

Numerous clinical conditions are also visible, such as autonomic dysfunction, mononeuropathies, and cranial nerve palsies. Current clinical research has demonstrated that persistent low-intensity inflammation is unquestionably important for DN. Studies on individuals with DN who do not experience pain have revealed that the latter group has increased levels of cytokines and inflammatory markers.[33] According to Magrinelli et al. DN patients exhibited elevated IL-6 and IL-10 levels, which were associated with certain abnormalities in big nerve fibers.[34] However, there appears to be a connection between the onset of nerve degeneration in DN and elevated levels of IL-6, IL-1, transforming growth factor-beta, and tumour necrosis factor.[4] Systemic inflammation has been found by Herder et al. to be predictive of the onset and course of DN over a period of 6.5 years.[35] They also found that Diabetic peripheral neuropathy (DPN) was associated with elevated levels of IL-6, soluble intracellular adhesion molecule-1 (ICAM-1), plasma high-sensitivity C-reactive protein, TNF-α and interleukin-1 receptor IL-1RA, and low levels of adiponectin. Herder et al. also recommended the use of IL-1RA and ICAM-1 as biomarkers to predict the course of DPN in diabetic patients, and they observed high levels of vascular cell adhesion molecule-1, chemokines, and E-selectin in DPN and progression. In another study, the inflammatory marker was analyzed in subjects who had been diagnosed with DPN for more or less than 8 years, and it was discovered that there was an inverse relationship between the subjects' TNF-α level and the nerve conduction velocities of the n. suralis, n. medianus, and n. ulnaris.[35] Serum TNF-α concentrations in diabetic neuropathy participants were greater than in control subjects, and the disease's duration tended to increase.[36]

A lot of attention has been placed on haematological indices in the scientific medical literature, including NLR, MLR, and PLR indexes such SII, SIRI, and all inflammatory index. NLR, MLR, PLR, and SII have emerged as useful vascular disease predictors among these inflammatory markers, according to analysis of recently published publications. In this regard, a number of studies have shown their prognostic value.[37-42] As a result of this study, inflammation markers especially such as SII, SIRI and NLR detected in the group with DN support the literature.

CONCLUSION

Diabetes-related inflammation and metabolic syndrome have the ability to accelerate the development of DN and discomfort. Only symptomatic pain relievers with varying degrees of effectiveness are now available, and there is still no authorized medication for the prevention or treatment of diabetic neuropathy. The primary pathogenic mechanism of diabetic neuropathy is inflammation. Inflammation and the onset of diabetic neuropathy are linked by intricate molecular networks and mechanisms. The investigation of the possibility of anti-inflammatory strategies for the suppression of neuropathy development will be made easier by developments in our knowledge of the functions of these important inflammatory molecules and pathways in diabetic neuropathy. The absence of a therapy questionnaire in the DN patient group is the primary research drawback.

Source of Finance

During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

Conflict of Interest

No conflicts of interest between the authors and / or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

REFERENCES

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14. PMID: 19896746.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53. PMID: 15111519.
3. Pop-Busui R, Ang L, Holmes C, et al. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep. 2016;16:29. PMID: 26897744; PMCID: PMC5127166.
4. Jin HY, Park TS. Role of inflammatory biomarkers in diabetic peripheral neuropathy. J Diabetes Investig. 2018;9(5):1016-8. PMID: 29277966; PMCID: PMC6123055.
5. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140:900-17. PMID: 20303879; PMCID: PMC2887297.
6. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11:738-49. PMID: 21984069; PMCID: PMC3383854.
7. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-46. PMID: 20148674.
8. Pitsavos C, Tampourlou M, Panagiotakos DB, et al. Association between low-grade systemic ınflammation and Type 2 diabetes mellitus among men and women from the ATTICA study. Rev Diabet Stud. 2007;4:98-104. PMID: 17823694; PMCID: PMC2036265.
9. Peirovy A, Malek Mahdavi A, Khabbazi A, et al. Clinical usefulness of hematologic indices as predictive parameters for systemic lupus erythematosus. Lab Med. 2020;51:519-28. PMID: 32073127.
10. Hao X, Li D, Wu D, et al. The Relationship between Hematological Indices and Autoimmune Rheumatic Diseases (ARDs), a meta-Analysis. Sci Rep. 2017;7:10833. PMID: 28883472; PMCID: PMC5589752.
11. Yang Z, Zhang Z, Lin F, et al. Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS. 2017;125:863-71. PMID: 28766758.
12. Ayna AB, Ermurat S, Coşkun BN, et al. Neutrophil to lymphocyte ratio and mean platelet volume as inflammatory indicators in systemic lupus erythematosus nephritis. Arch Rheumatol. 2016;32:21-5. PMID: 30375538; PMCID: PMC6190939.
13. Geng Y, Zhu D, Wu C, et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2018;65:503-10. PMID: 30408627.
14. Xie QK, Chen P, Hu WM, et al. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J Transl Med. 2018;16:273. PMID: 30286769; PMCID: PMC6172841.
15. Erdoğan M, Erdöl MA, Öztürk S, et al. Systemic immune-inflammation index is a novel marker to predict functionally significant coronary artery stenosis. Biomark Med. 2020;14:1553-61. PMID: 33179524.
16. Liu Y, Ye T, Chen L, et al. Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease. Coron Artery Dis. 2021;32:715-20. PMID: 33826540.
17. Candemir M, Kiziltunç E, Nurkoç S, et al. Relationship between systemic immune-inflammation index (SII) and the severity of stable coronary artery disease. Angiology. 2021;72:575-81. PMID: 33685239.
18. Huang J, Zhang Q, Wang R, et al. Systemic immune-inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. Med Sci Monit. 2019;25:9690-701. PMID: 31849367; PMCID: PMC6930700.
19. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-22. PMID: 25271081.
20. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147-57. PMID: 11323136.
21. Yang R, Chang Q, Meng X, et al. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9:3295-302. PMID: 30271489; PMCID: PMC6160683.
22. Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261-72. PMID: 28974892; PMCID: PMC5603492.
23. Geng Y, Shao Y, Zhu D, et al. Systemic Immune-Inflammation Index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis. Sci Rep. 2016;6:39482. PMID: 28000729; PMCID: PMC5175190.
24. Hong X, Cui B, Wang M, et al. Systemic Immune-inflammation Index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 2015;236:297-304. PMID: 26250537.
25. Liu J, Liu X, Li Y, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. Biosci Rep. 2018;38:BSR20180172. PMID: 29581246; PMCID: PMC6019380.
26. Liu J, Liu X, Li Y, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. Biosci Rep. 2018;38:BSR20180172. PMID: 29581246; PMCID: PMC6019380.
27. Phillipson M, Kubes P. The neutrophil in vascular inflammation. Nat Med. 2011;17:1381-90. PMID: 22064428; PMCID: PMC7095830.
28. Shanmugam N, Reddy MA, Guha M, et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 2003;52:1256-64. PMID: 12716761.
29. Guha M, Bai W, Nadler JL, et al. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem. 2000;275:17728-39. PMID: 10837498.
30. Hofmann MA, Schiekofer S, Kanitz M, et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care. 1998;21:1310-6. PMID: 9702439.
31. Kedziora-Kornatowska KZ. Production of superoxide and nitric oxide by granulocytes in non-insulin-dependent diabetic patients with and without diabetic nephropathy. IUBMB Life. 1999;48:359-62. PMID: 10690652.
32. Korpinen E, Groop PH, Fagerudd JA, et al. Increased secretion of TGF-beta1 by peripheral blood mononuclear cells from patients with Type 1 diabetes mellitus with diabetic nephropathy. Diabet Med. 2001;18:121-5. PMID: 11251675.
33. Doupis J, Lyons TE, Wu S, et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94:2157-63. PMID: 19276232; PMCID: PMC2690431.
34. Magrinelli F, Briani C, Romano M, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res. 2015;2015:547834. PMID: 25961054; PMCID: PMC4415740.
35. Herder C, Kannenberg JM, Huth C, et al. Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. Diabetes Care. 2017;40(4):569-76. PMID: 28174259.

36. Hussain G, Rizvi SA, Singhal S, et al. Serum levels of TNF-α in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus. Diabetes Metab Syndr. 2013;7:238-42. PMID: 24290092.

37. Roumeliotis S, Neofytou IE, Maassen C, et al. Association of red blood cell distribution width and neutrophil-to-lymphocyte ratio with calcification and cardiovascular markers in chronic kidney disease. Metabolites. 2023;13:303. PMID: 36837922; PMCID: PMC9966770.

38. Halmaciu I, Arbănași EM, Kaller R, et al. Chest CT severity score and systemic inflammatory biomarkers as predictors of the need for invasive mechanical ventilation and of COVID-19 patients' mortality. Diagnostics (Basel). 2022;12:2089. PMID: 36140490; PMCID: PMC9497509.

39. Mureșan AV, Russu E, Arbănași EM, et al. The predictive value of nlr, mlr, and plr in the outcome of end-stage kidney disease patients. Biomedicines. 2022;10:1272. PMID: 35740294; PMCID: PMC9220159.

40. Mureșan AV, Hălmaciu I, Arbănași EM, et al. Prognostic Nutritional Index, Controlling Nutritional Status (CONUT) Score, and inflammatory biomarkers as predictors of deep vein thrombosis, acute pulmonary embolism, and mortality in COVID-19 patients. Diagnostics (Basel). 2022;12:2757. PMID: 36428817; PMCID: PMC9689150.

41. Arbănași EM, Mureșan AV, Coșarcă CM, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio impact on predicting outcomes in patients with acute limb ischemia. Life (Basel). 2022;12:822. PMID: 35743853; PMCID: PMC9225565.

42. Melinte RM, Arbănași EM, Blesneac A, et al. Inflammatory biomarkers as prognostic factors of acute deep vein thrombosis following the total knee arthroplasty. Medicina (Kaunas). 2022;58:1502. PMID: 36295662; PMCID: PMC9608310.